who vip webinar 2011 1 evaluation considerations: measures & methods shrikant i. bangdiwala, phd...

75
WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention Research Center University of North Carolina at Chapel Hill, USA presented at

Upload: austin-blevins

Post on 27-Mar-2015

221 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 20111

Evaluation Considerations: Measures & Methods

Shrikant I. Bangdiwala, PhD

Professor of Research in BiostatisticsInjury Prevention Research CenterUniversity of North Carolina at Chapel Hill, USA

presented at

Page 2: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 20112

Content

Purpose of evaluation Cycle of program planning & evaluation Indicators Study designs Statistical modeling Challenges

Page 3: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

Safety 2010 London3

What are we ‘evaluating’?

Actions, programs, activities Conducted in a community setting, over a

period of time Aimed at reducing deaths, injuries, and/or

events and behaviors that cause injuries

WHO VIP Webinar 20113

Page 4: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 20114

Example: Suwon, South Korea

area of ‘safety promotion’

http://www.phs.ki.se/csp/safecom/suwon2.htm

Page 5: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 20115

Why do we ‘evaluate’?

To know ourselves what works and if we are doing some goodIn performing some activityIn the communityIn the country

To convince funders and supporters that their investment is worthwhile

To convince the community about the benefits of the multiple activities and actions carried out

Page 6: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 20116 NSC Chicago 2010 6

Main purposes of evaluation

Evaluation helps determine:How well a program/policy works relative to its

goals & objectivesWhy a program/policy did or didn’t work, relative

to planned processHow to restructure a program/policy to make it

work, or work betterWhether to change funding for a program

Page 7: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 20117

Methodological complications

Multiplicities Multiple components of a programMultiple populations at riskMultiple study designsMultiple types of effects/impacts/outcomes &

severitiesMultiple audiences/objectives of ‘evaluation’Multiple methods for conducting evaluation

Page 8: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 20118 8

When should evaluation be considered? Evaluation needs to begin in, and be part of,

the planning process… Otherwise, “if you do not know where you are

going, it does not matter which way you go, and you will never know if you got there or not!”

Lewis Carroll (1872)

Alice in Wonderland

Adapted from M. Garrettson

Page 9: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 20119 NSC Chicago 2010 9

ProgramPlanningPhase

Formative EvaluationHow can the program activities be improved before

implementation?

Process EvaluationHow is/was the program (being) implemented?

PostProgramPhase

Impact / OutcomeDid the program succeed in achieving the intended

impact or outcome?

Program Implementation

Phase

Types of evaluation depending on program phase

Page 10: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201110

Cycle of program planning and evaluation

Adapted from C Runyan

Page 11: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201111 11

Identify population & problem Surveillance data Other needs assessment strategies

key informant interviewsfocus groupssurveys evaluations of past programs literatureconsultation with peersother info…

Page 12: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201112 NSC Chicago 2010 12

Test & refineimplementation

Test, Refine,Implement

Choose strategies

Set goals/objectives

Disseminate

Identifyproblem

& population

Define target audience

Evaluation: •Formative

Implement

Identify resources

Evaluation:•Process•Impact•Outcome

Page 13: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201113 13

Define target audience

To whom is the program directed?Whose injuries need to be reduced?Who is the target of the program?

• at risk persons• care givers (e.g. parents)• general public• media• decision makers

Page 14: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201114 14

Understand target audience

What are their characteristics?Special needs (e.g. literacy)Interests, concerns, prioritiesAttitudes & beliefs re: problem & solutions to

problem Cultural issues

Page 15: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201115 15

Test & refineimplementation

Test, Refine,Implement

Choose strategies

Set goals/objectives

Disseminate

Identifyproblem

& population

Define target audience

Evaluation: •Formative

Implement

Identify resources

Evaluation:•Process•Impact•Outcome

Page 16: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201116 16

Identify resources

Community partnersinterest in topicworking on similar projects

On-going activities Sources of financial support Interests in community

Page 17: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201117 17

Test & refineimplementation

Test, Refine,Implement

Choose strategies

Set goals/objectives

Disseminate

Identifyproblem

& population

Define target audience

Evaluation: •Formative

Implement

Identify resources

Evaluation:•Process•Impact•Outcome

Page 18: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201118 18

Set goals & objectives

Goalbroad statement of what program is trying to

accomplish

ObjectivesSpecificMeasurableTime-framed

Page 19: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201119 19

Test & refineimplementation

Test, Refine,Implement

Choose strategies

Set goals/objectives

Disseminate

Identifyproblem

& population

Define target audience

Evaluation: •Formative

Implement

Identify resources

Evaluation:•Process•Impact•Outcome

Page 20: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201120 20

Choose Strategies

Identify existing strategies/programsLiterature: evidence based? promising practice?WHO manualsSuccesses from other communities-regions-

countries Develop new strategies:

Logic model (how would it work)Haddon matrix

Page 21: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201121 21

Haddon Matrix

Person Vehicle/vector

Physical Environ.

Social Environ.

Pre-event

Event

Post-event

Haddon 1970 Am J Public Health

Page 22: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201122 22

Pre-Event Other??

Decision CriteriaDecision Criteria

PhasesPhases

3-dimensional Haddon Matrix

P

erso

n

Veh

icle

/V

ecto

r)

P

hysi

cal

Env

iron.

Soc

ial

Env

iron.

FactorsFactors

Event

Post-event

FeasibilityPreferences

StigmatizationEquity

FreedomCost

Effectiveness

Runyan 1998 Injury Prevention

Page 23: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201123 NSC Chicago 2010 23

Test & refineimplementation

Test, Refine,Implement

Choose strategies

Set goals/objectives

Disseminate

Identifyproblem

& population

Define target audience

Evaluation: •Formative

Implement

Identify resources

Evaluation:•Process•Impact•Outcome

Page 24: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201124 24

Formative Evaluation

What is the best way to influence the target population?

Will the activities reach the people intended, be understood and accepted by target population?

How can activities be improved?

Improves (pilot-tests) program activities before full-scale implementation

May increase likelihood program or policy will succeed

May help stretch resources

Why it’s usefulQuestions it answers

* Modified from Thompson & McClintock, 2000

Page 25: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201125 NSC Chicago 2010 25

Test & refineimplementation

Test, Refine,Implement

Choose strategies

Set goals/objectives

Disseminate

Identifyproblem

& population

Define target audience

Evaluation: •Formative

Implement

Identify resources

Evaluation:•Process•Impact•Outcome

Page 26: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201126 26

Implementation

As planned, with attention to detail

Documented clearly so others can replicate if appropriate

Page 27: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201127 NSC Chicago 2010 27

Test & refineimplementation

Test, Refine,Implement

Choose strategies

Set goals/objectives

Disseminate

Identifyproblem

& population

Define target audience

Evaluation: •Formative

Implement

Identify resources

Evaluation:•Process•Impact•Outcome

Page 28: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201128 28

Process evaluation

Purpose is to address:What was done?How was it implemented?How well was it implemented?Was it implemented as planned?

Page 29: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201129 29

Process evaluation – examples of questions

• Who carried out intervention?• Was this the appropriate person/group?• Who supported and opposed intervention?• What methods/activities were used?

Page 30: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201130 30

Process evaluation - why is it useful?

• Allows replication of programs that work.• Helps understand why programs fail.

* Modified from Thompson & McClintock, 2000

Page 31: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201131 31

The intervention cannot be a black box…

OutcomeIdea ?

It must be clearly understood

Page 32: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201132 NSC Chicago 2010 32

Test & refineimplementation

Test, Refine,Implement

Choose strategies

Set goals/objectives

Disseminate

Identifyproblem

& population

Define target audience

Evaluation: •Formative

Implement

Identify resources

Evaluation:•Process•Impact•Outcome

Page 33: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201133 33

Impact evaluation

Purpose is to address changes in: knowledge attitudes beliefs/ values skills behaviors / practices

Page 34: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201134 34

Using impact measures for

Establishing effectivenessSuppose we have a public safety campaign as our

strategyNeed to show Campaign Behavior Outcome

If we already have demonstrated that Behavior Outcome

We simply need to show Campaign Behavior

Page 35: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201135 35

Outcome evaluation

Purpose is to address changes in:injury events (e.g. frequency, type, pattern) morbidity (e.g. frequency, severity, type)mortality (e.g. frequency, time to death)cost (e.g. direct and indirect)

Page 36: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201136 NSC Chicago 2010 36

OutcomesImpacts Intervention

Physician counseling

parents

Enforcement of helmet law

Media campaign

Parental attitudes

toward child helmet use

Purchase of helmets

Use of helmets by children

Head injury in bike crashes

Deaths from head injury in crashes

Example: Bike helmets

Page 37: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201137 37

Evaluation examples of questions for local policy of smoke alarms

Did the local policy of smoke alarms in apartments… Get passed Where people aware of it? Did people have access to smoke alarms? Did people get them installed properly? Do people keep them maintained? Lead to a reduction in the number or rates of:

events (e.g. apartment fires) injuries deaths costs (e.g. burn center costs, family burden, property loss)

Page 38: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 2011383838

Evaluation – selection of measures‘Quantitative Indicators’

Process Impact Outcome

Health related Financial

Page 39: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201139

Choice of measure or indicator

We need to choose appropriate impact and outcome measures ‘Soft’ (more difficult to measure) outcomes –

Perceptions constructs: fear, insecurity, wellbeing, quality of life Knowledge, attitudes and behaviors constructs

Hard outcomes – Deaths, hospitalizations, disabilities due to injuries and violence Societal impacts – local development indicators

Economics outcomes – Direct $/€/£/¥, indirect DALYs, QALYs, opportunities lost, burdens

Page 40: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201140

Evidence of effectiveness

Obtain qualitative ‘evidence’ to complement the quantitative ‘evidence’Ex. Are “multisectorial collaborations and

partnerships” friendly and functioning well?Ex. Is “community participation” optimal?

Incorporate process indicators Incorporate narratives & testimonials

Page 41: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201141 NSC Chicago 2010 41

Test & refineimplementation

Test, Refine,Implement

Choose strategies

Set goals/objectives

Disseminate

Identifyproblem

& population

Define target audience

Evaluation: •Formative

Implement

Identify resources

Evaluation:•Process•Impact•Outcome

Page 42: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201142 42

Dissemination

Dissemination not done wellNot attemptedNot based on research about how to disseminate

information to intended audience Dissemination done well

Defining audienceHow to access audienceHow best to communicate change message to themPresentation of clear, straightforward messages

Page 43: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 2011434343

Evaluation measures

Lead to evidence of effectiveness But only if the research and study

methodologies, and the statistical analyses methodologies, are appropriate to convince the funders and supporters, the skeptics, the stakeholders, the communityand understandable

Page 44: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201144

Research methodology approach:Evidence of effectiveness

Obtain quantitative ‘evidence’ that favors the hypothesis that the intervention is effective as opposed to the (null) hypothesis that the intervention is not effective.

How? Experimental study designs - randomized clinical trials,

grouped randomized experiments, community-randomized studies

Quasi-experimental study designs - non-randomized comparative studies, before-after studies

Observational studies - cohort studies, case-control studies and comparative cross-sectional studies

Page 45: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 2011454545

Randomized controlled trial (RCT) / Experiment

‘strongest’ evidence

Randomize

InterventionGroup

Control Group

O X O

O OX’

Page 46: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 2011464646

Quasi-experimental designs

‘qualified’ evidence

Intervention Group

Comparison Group

O X O

O O

Page 47: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 2011474747

One group pre/post

‘weak’ evidence

InterventionGroup

O X O

Page 48: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 2011484848

One group – multiple pre / multiple post

better ‘weak’ evidenceIntervention

GroupO O O X O O O O O

Page 49: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 2011494949

One group, post only

‘basically ignorable’ evidence

Intervention Group

X O

Page 50: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

Safety 2010 London505050

Observational designs- cohort study

evidence?Self-chosen Intervention Group

Self-chosen Non-intervention Group

X X X

O O O

WHO VIP Webinar 201150

Page 51: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

Safety 2010 London515151

Observational designs- case-control study

evidence? Cases

Controls

X

O

X

O

WHO VIP Webinar 201151

Page 52: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

Safety 2010 London525252

Observational designs- cross-sectional study

evidence?

InjuredX X O XO

O X OO O

Non-injured

WHO VIP Webinar 201152

Page 53: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201153

Statistical analysis methodologies

Choice - often guided by what has been done previously, or what is feasible to do, or easy to explain

Choice should be tailored to the audience & their ability to understand results; but also on the ability of the presenter to explain the methodologies

Page 54: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201154

Statistical analysis Determined by research question(s) Guided by study design – experimental or observational

Group randomized controlled experiment Non-randomized comparison study Single site pre/post; surveillance study Retrospective or cross-sectional

Guided by whether outcome is studied at a single time point or multiple time points Time series analyses

Guided by audience Visual and descriptive appreciation

Page 55: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201155

Visual and descriptive analysis – longitudinal time series

Example:

Espitia et al (2008) Salud Pública Mexico

Page 56: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

Safety 2010 London56

Visual and descriptive analysis – comparisons over time

Example:

www.gapminder.org

WHO VIP Webinar 201156

Page 57: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201157

Statistical analysis - challenge

But what we as a field have not done as well as other fields, is to draw strength from numbers develop collective evidence

Combine results from multiple studiesSystematic reviews (of observational studies)Meta analysis (of experimental & observational studies)Meta regression (of heterogeneous studies)Mixed treatment meta regression (for indirect

comparisons)

Page 58: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201158

Systematic reviews

A protocol driven comprehensive review and synthesis of data focusing on a topic or on related key questions formulate specific key questions developing a protocol refining the questions of interest conducting a literature search for evidence selecting studies that meet the inclusion criteria appraising the studies critically synthesizing and interpreting the results

Page 59: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201159

Example – Systematic review

Shults et al (2001) Amer J Prev Med

Page 60: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201160

Systematic reviews

Of particular value in bringing together a number of separately conducted studies, sometimes with conflicting findings, and synthesizing their results.

To this end, systematic reviews may or may not include a statistical synthesis called meta-analysis, depending on whether the studies are similar enough so that combining their results is meaningful Green (2005) Singapore Medical Journal

Zaza et al (2001) Amer. J Preventive Medicine – motor vehicle

Page 61: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201161

Meta analysis

A method of combining the results of studies quantitatively to obtain a summary estimate of the effect of an interventionOften restricted to randomized controlled trialsRecently, the Cochrane Collaboration is

‘branching out’ to include both experimental and observational studies in meta analyses

Page 62: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201162

Meta analysis

e.g. Liu et al (2008) Cochrane Collaboration

Page 63: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201163

Meta analysis

The combining of results should take into account: the ‘quality’ of the studies

• Assessed by the reciprocal of the variance the ‘heterogeneity’ among the studies

• Assessed by the variance between studies

Page 64: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201164

Meta analysis – estimation of effect

The estimate is a weighted average, where the weight of a study is the reciprocal of its variance

In order to calculate the variance of a study, one can use either a ‘fixed’ effects model or a ‘mixed’/’random’ effects model Fixed effects model:

utilizes no information from other studies Random effects model:

considers variance among and within studies

*2

2

)var(

)var(

iYi

iii

VY

eY

Borenstein et al (2009) Introduction to Meta Analysis

iYii VeY )var()var(

Page 65: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201165

Meta analysis & meta regression

Dealing with ‘heterogeneity’ among the studies - 2 Decompose the total variance into among and within

components using mixed effects models for getting a more precise estimate of the intervention effect

If there is still residual heterogeneityExpand the mixed effects model to include study-level

covariates that may explain some of the residual variability among studies meta regression

Page 66: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201166

Meta regression

e.g.

iiiii eXXY 2211

Overall mean

X1 study variable – EU/USA

X2 study variable – population type

study random effect

random error

Page 67: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201167

Meta analysis

Standard meta-analytical methods are typically restricted to comparisons of 2 interventions using direct, head-to-head evidence alone.

So, for example, if we are interested in the Intervention A vs Intervention B comparison, we would include only studies that compare Intervention A versus Intervention B directly.

Many times we have multiple types of interventions for the same type of problem, and we hardly have head-to-head comparisons

We may also have multiple component interventions

Page 68: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201168

Mixed treatment meta analysis

Let the outcome variable be a binary response 1 = positive response 0 = negative response

We can calculate the binomial counts out of a total number at risk on the kth intervention in the jth study

We can then calculate

the estimated probability of the outcome (risk of response) for the kth intervention in the jth study

kj

kjkj n

rp

:

::

kjr :kjn :

Welton et al 2009 Amer J Epid

Page 69: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201169

Mixed treatment meta analysis

Let each study have a reference ‘‘standard’’ intervention arm, sj, with study-specific ‘‘standard’’ log odds of outcome, j .

The log odds ratio, j:k, of outcome for intervention k, relative to standard sj, is assumed to come from a random effects model with mean log odds ratio , and between-study standard deviation

where dk is the mean log odds ratio of outcome for intervention k relative to control (so that d1 = 0).

)(jsk dd

Welton et al 2009 Amer J Epid

Page 70: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201170

Mixed treatment meta analysis

This leads to the following logistic regression model:

where ]),[(~: jskkj ddN

k

s

p

p

kjj

jj

kj

kj

int

int

1ln

::

:

Welton et al 2009 Amer J Epid

Page 71: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201171

Mixed treatment meta analysis- multiple-methods interventions

If we have multiple methods in the ith intervention

Plus we have multiple times when the outcome is assessed

itiititiit eXMMtY 423121

,...,, 321 iii MMM

Study effect

Time effect

Components 1 & 2 effects

Study covariable

Error term

Page 72: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201172

Statistical analysis

Methodology does exist for developing stronger collective evidence, evaluating the effectiveness of community based interventions, using different types of study designs and interventions

Developing “practice-based evidence”

Page 73: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

Safety 2010 London73

Dissemination

We should not stop at developing the evidence We must work alongside economists in developing

ways to effectively communicate ‘what works’ methodology and cost models do exist for estimating the “return on investment”

Money talks !!

WHO VIP Webinar 201173

Page 74: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201174

Challenges – Evaluation requires

Integration of evaluation from the beginning Appropriate measures, possible to be collected objectively,

unbiasedly, easily and with completeness Appropriate qualitative and process information, to complement

the quantitative information Concrete and convincing evidence of what aspects work in

individual communities Formal methodological statistical evaluation of specific elements

of programs Collective evidence of what common elements of programs work Effective dissemination strategies – “return on investment”

Page 75: WHO VIP Webinar 2011 1 Evaluation Considerations: Measures & Methods Shrikant I. Bangdiwala, PhD Professor of Research in Biostatistics Injury Prevention

WHO VIP Webinar 201175 75